


Claims

1. A compound of the formula:



5

or a pharmaceutically acceptable salt thereof, in which:

- 10 A, along with X and the carbon atom to which it is attached, forms a (C₆-C₁₀)aryl or a 5- to 10-membered heteroaryl moiety, in which said aryl or heteroaryl moiety is optionally substituted with up to 4 substituents, each independently selected from the group consisting of

C₃-C₆ cycloalkyl, oxo, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ alkoxy, hydroxy, cyano, halo, -NR⁵R⁶, -C(O)-NR⁵R⁶, -NH-C(O)R⁵, -C(O)-OR⁵, -(C₁-C₆)alkyl-(C₃-C₆)cycloalkyl, a 4- to 6-membered heterocyclic moiety, phenyl, and benzyl;

- 15 X is represented by N or C;

- R¹ is represented by C₁-C₆ alkyl, (C₆-C₁₀)aryl or a 5- to 6-membered heterocyclic moiety, in which said alkyl, aryl or heterocyclic moiety may be optionally substituted with up to 4 substituents, each independently selected from the group consisting of halogen, optionally substituted C₁-C₆ alkyl, optionally substituted C₁-C₆ alkoxy, hydroxy, cyano, -NR⁵R⁶, -C(O)-NR⁵R⁶, -NH-C(O)R⁵, and -C(O)-OR⁵;

- 20 R² and R³ are each independently represented by hydrogen, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ alkoxy;

- R⁴, if present, is optionally represented by up to 2 substituents, each independently selected from the group consisting of fluoro, hydroxy, optionally substituted C₁-C₆ alkyl, or optionally substituted C₁-C₆ alkoxy, and;

25 R⁵ and R⁶ are each optionally and independently represented by hydrogen or C₁-C₆ alkyl.

2. A compound, or a pharmaceutically acceptable salt thereof, according to claim 1 in which R² is methyl.

3. A compound, or a pharmaceutically acceptable salt thereof, according to claim 1 or 2 in which R³ is hydrogen.
4. A compound, or a pharmaceutically acceptable salt thereof, according to claim 1, 2 or 3 in which R¹ is represented by phenyl, which may be optionally substituted.
5. A compound, or a pharmaceutically acceptable salt thereof, according to claim 4, in which said phenyl ring is substituted with one or more substituents selected from the group consisting of methyl, fluoro, methoxy, and chloro.
6. A compound, or a pharmaceutically acceptable salt thereof, according to claim 1, 2 or 3 in which R¹ is tetrahydrofuran.
7. A compound, or a pharmaceutically acceptable salt thereof, according to claim 6 in which said tetrahydrofuran is unsubstituted.
8. A compound, or a pharmaceutically acceptable salt thereof, according to claim 1, 2, or 3 in which R¹ is tetrahydropyran.
9. A compound, or a pharmaceutically acceptable salt thereof, according to claim 8, in which said tetrahydropyran is unsubstituted.
10. A compound, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 9 in which A, along with X and the carbon atom to which it is attached, forms a phenyl ring.
11. A compound, or a pharmaceutically acceptable salt thereof, according to any one of claims 1 to 9 in which A, along with X and the carbon atom to which it is attached, forms a heteroaryl moiety.
12. A compound, or a pharmaceutically acceptable salt thereof, according to claim 11 in which said heteroaryl moiety contains at least one nitrogen atom.
13. A compound, or a pharmaceutically acceptable salt thereof, according to claim 11 in which said heteroaryl moiety is selected from the group consisting of pyridine, pyridazine, pyrimidine, and pyrazine.

14. A compound, or a pharmaceutically acceptable salt thereof, according to claim 11 in which said heteroaryl moiety is selected from the group consisting of pyrrole, pyrazole, imidazole, isoxazole, oxazole, isothiazole, and thiazole.
- 5 15. A compound, or a pharmaceutically acceptable salt thereof, according to claim 10 in which said phenyl ring is substituted with one or more substituents selected from the group consisting of methyl, methoxy, chloro, fluoro, 2-fluoroethoxy, cyano, -C(O)-OH, -C(O)-NH₂, and trifluoromethyl.
- 10 16. A compound, or a pharmaceutically acceptable salt thereof, according to claim 11 in which said heteroaryl is substituted with one or more substituents selected from the group consisting of methyl, ethyl, trifluoromethyl, difluoromethyl, difluoromethoxy, methoxy, isopropyl, cyclopropyl, oxo, hydroxy, ethoxy, phenyl, 2-trifluoroethyl, dimethylamino, cyclobutylmethyl, methylamino, and cyclopentyl.
17. A compound, or a pharmaceutically acceptable salt thereof, according to any one of claims 1-16 in which R⁴ is absent.
- 15 18. A compound according to claim 1 selected from the group consisting of:
 - i) 4-(3-cyclopropyl-6,7-dihydro[1,2]oxazolo[4,3-c]pyridin-5(4*H*)-yl)-7-methyl-5-[(3*S*)-tetrahydrofuran-3-yl]imidazo[5,1-*f*][1,2,4]triazine,
 - ii) 4-(2-cyclopropyl-2,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-c]pyridin-5-yl)-7-methyl-5-[(3*S*)-tetrahydrofuran-3-yl]imidazo[5,1-*f*][1,2,4]triazine,
 - 20 iii) 4-(3-cyclopropyl-1-methyl-1,4,6,7-tetrahydro-5*H*-pyrazolo[4,3-c]pyridin-5-yl)-7-methyl-5-[(3*S*)-tetrahydrofuran-3-yl]imidazo[5,1-*f*][1,2,4]triazine,
 - iv) 2-cyclopropyl-6-[5-(2-fluorophenyl)-7-methylimidazo[5,1-*f*][1,2,4]triazin-4-yl]-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidine,
 - v) 4-(2-cyclopropyl-6,7-dihydro[1,3]oxazolo[5,4-c]pyridin-5(4*H*)-yl)-7-methyl-5-[(3*S*)-tetrahydrofuran-3-yl]imidazo[5,1-*f*][1,2,4]triazine,
 - 25 vi) 8-(2-fluoroethoxy)-7-methoxy-2-{7-methyl-5-[(3*S*)-tetrahydrofuran-3-yl]imidazo[5,1-*f*][1,2,4]triazin-4-yl}-1,2,3,4-tetrahydroisoquinoline,
 - vii) 5-(2-fluorophenyl)-7-methyl-4-(1-methyl-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-c]pyridin-6-yl)imidazo[5,1-*f*][1,2,4]triazine,

- viii) 7-methyl-4-(1-methyl-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridin-6-yl)-5-[(3*S*)-tetrahydrofuran-3-yl]imidazo[5,1-*f*][1,2,4]triazine,
- ix) 4-(1-cyclopropyl-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridin-6-yl)-7-methyl-5-[(3*S*)-tetrahydrofuran-3-yl]imidazo[5,1-*f*][1,2,4]triazine, and;
- 5 x) 7-methyl-4-(1-methyl-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridin-6-yl)-5-[(2*R*)-tetrahydrofuran-2-yl]imidazo[5,1-*f*][1,2,4]triazine,

or a pharmaceutically acceptable salt thereof.

- 19. A compound according to claim 1 which is 7-{7-methyl-5-[(3*S*)-tetrahydrofuran-3-yl]imidazo[5,1-*f*][1,2,4]triazin-4-yl}-5,6,7,8-tetrahydro-1,7-naphthyridine, or a
10 pharmaceutically acceptable salt thereof.
- 20. A compound according to claim 1 which is 7-methyl-4-(1-methyl-1,4,5,7-tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridin-6-yl)-5-[(3*S*)-tetrahydrofuran-3-yl]imidazo[5,1-*f*][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.
- 21. A compound according to claim 1 which is 7-methyl-4-(1-methyl-1,4,5,7-
15 tetrahydro-6*H*-pyrazolo[3,4-*c*]pyridin-6-yl)-5-[(2*R*)-tetrahydrofuran-2-yl]imidazo[5,1-*f*][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.
- 22. A compound according to claim 1 which is 8-(2-fluoroethoxy)-7-methoxy-2-{7-methyl-5-[(3*S*)-tetrahydrofuran-3-yl]imidazo[5,1-*f*][1,2,4]triazin-4-yl}-1,2,3,4-tetrahydroisoquinoline, or a pharmaceutically acceptable salt thereof.
- 20 23. A compound according to claim 1 which is 4-(2-cyclopropyl-6,7-dihydro[1,3]oxazolo[5,4-*c*]pyridin-5(4*H*)-yl)-7-methyl-5-[(3*S*)-tetrahydrofuran-3-yl]imidazo[5,1-*f*][1,2,4]triazine, or a pharmaceutically acceptable salt thereof.
- 24. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt, according to any one of claims 1-23 in association with one, or
25 more, pharmaceutical excipients.
- 25. A compound according to any one of claims 1-23 or a pharmaceutically acceptable salt thereof for use in the treatment of a disease selected from psychoses, Parkinson's disease, dementias, Huntington's disease, obsessive compulsive disorder, tardive dyskinesia, chorea, depression, mood disorders,

impulsivity, drug addiction, attention deficit/hyperactivity disorder (ADHD), depression with parkinsonian states, personality changes with caudate or putamen disease, dementia and mania with caudate and pallidal diseases and compulsions with pallidal disease.

- 5 26. A compound for use according to claim 25 wherein the disease is Huntington's disease.